Related Experiment Video
Updated: Dec 14, 2025
04:30
Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat
Published on: February 4, 2021
3.6K
Immunological therapeutics in acute aortic syndrome
Lara Jane Rimmer1, Saad Moughal1, Mohamad Bashir1
1Vascular Surgery Department, 155510Royal Blackburn Teaching Hospital, Blackburn, UK.
Asian Cardiovascular & Thoracic Annals
|July 18, 2020
Summary
Acute aortic syndrome management is exploring anti-inflammatory drugs and stem cell therapies. Pharmacogenomics may personalize treatments for diverse patient genomes.
Area of Science:
- Cardiovascular Medicine
- Immunology
- Pharmacology
Background:
- Acute aortic syndrome encompasses aortic dissection, penetrating atherosclerotic ulcer, and intramural hematoma.
- Inflammatory pathways are implicated as a primary cause of acute aortic syndrome.
- Current research focuses on novel therapeutic targets and personalized medicine.
Purpose of the Study:
- To review current pharmacological management strategies for acute aortic syndrome.
- To highlight emerging research in inflammatory pathways and stem cell therapies.
- To explore the potential of pharmacogenomics in tailoring treatments.
Main Methods:
- Literature review of recent studies on acute aortic syndrome.
- Analysis of research on immunological markers and their therapeutic implications.
- Examination of stem cell research and pharmacogenomic applications.
Main Results:
- Pharmacological interventions targeting inflammatory pathways show promise.
- Interleukins, matrix metalloproteinases, and colony-stimulating factors are key research areas.
- Stem cell research and pharmacogenomics offer future therapeutic avenues.
Conclusions:
- Targeting inflammation is crucial for managing acute aortic syndrome.
- Novel therapies including stem cells and pharmacogenomics are advancing treatment possibilities.
- Personalized medicine approaches will likely improve patient outcomes.
Related Concept Videos
01:25Aortic Regurgitation III: Medical Management
233
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
233
01:14Myocarditis III: Medical Management
102
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
102
01:15Aortic Regurgitation I: Introduction
302
IntroductionAortic regurgitation is characterized by the backward flow of blood from the aorta into the left ventricle during diastole and arises from the improper closure of the aortic valve. This condition results in left ventricular volume overload and can stem from both acute and chronic etiologies, each contributing uniquely to the disease's progression and symptomatology.Acute and Chronic CausesAcute aortic regurgitation often results from events that suddenly impair the integrity of the...
302
01:28Acute Coronary Syndrome IV: Interprofessional Care
144
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
144
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
773
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
773
01:17Pericarditis III: Medical Management
177
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
177